公司简介
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre...
关联新闻
- Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management ...
- Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.